- Investment bank adds to health-care M&A team in New York
- Houlihan Lokey went public in August to fuel expansion
Houlihan Lokey Inc., the firm that went public in August, hired Goldman Sachs Group Inc. dealmaker Fedora Baloiu to the new role of head of the biopharmaceutical practice.
Baloiu is reporting to Mark Francis, head of the health-care group, according to a statement Monday from Los Angeles-based Houlihan Lokey. She spent nine years at Goldman Sachs focusing on pharmaceutical and biotech clients and previously was at Bain & Co, working on more than $65 billion worth of mergers-and-acquisitions and financing transactions in her career, Houlihan Lokey said.
Houlihan Lokey has been expanding its M&A team as industrywide deal volumes are near records, fueled in part by transactions in the health-care industry. The investment bank, which was founded in the 1970s and worked on some of the world’s largest bankruptcies, has also added talent for strategic consulting, private finance and dealmaking in the entertainment industry.
Baloiu’s “client relationships and depth of expertise in biopharmaceutical sector is tremendously valuable in both U.S. and Europe, where we see a sustained high level of M&A activity,” Francis said in the statement.
Baloiu is based in New York, Houlihan Lokey said. Her work at Goldman Sachs included a stint in London, according to the statement.